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Abstract
Background: The renin-angiotensin-aldosterone system (RAAS) is involved in the cardiovascular homeostasis as shown
by previous studies reporting a positive association between specific RAAS genotypes and an increased risk of myocardial
infarction. Anyhow the prognostic role in a long-term follow-up has not been yet investigated.
Aim of the study was to evaluate the influence of the most studied RAAS genetic Single Nucleotide Polymorphisms
(SNPs) on the occurrence and the long-term prognosis of acute myocardial infarction (AMI) at young age in an Italian
population.
Methods: The study population consisted of 201 patients and 201 controls, matched for age and sex (mean age 40 ± 4
years; 90.5% males). The most frequent conventional risk factors were smoke (p < 0.001), family history for coronary
artery diseases (p < 0.001), hypercholesterolemia (p = 0.001) and hypertension (p = 0.002). The tested genetic
polymorphisms were angiotensin converting enzyme insertion/deletion (ACE I/D), angiotensin II type 1 receptor
(AGTR1) A1166C and aldosterone synthase (CYP11B2) C-344T. Considering a long-term follow-up (9 ± 4 years) we
compared genetic polymorphisms of patients with and without events (cardiac death, myocardial infarction,
revascularization procedures).
Results: We found a borderline significant association of occurrence of AMI with the ACE D/I polymorphism (DD
genotype, 42% in cases vs 31% in controls; p = 0.056). DD genotype remained statistically involved in the incidence of
AMI also after adjustment for clinical confounders.
On the other hand, during the 9-year follow-up (65 events, including 13 deaths) we found a role concerning the AGTR1:
the AC heterozygous resulted more represented in the event group (p = 0.016) even if not independent from clinical
confounders. Anyhow the Kaplan-Meier event free curves seem to confirm the unfavourable role of this polymorphism.
Conclusion: Polymorphisms in RAAS genes can be important in the onset of a first AMI in young patients (ACE,
CYP11B2 polymorphisms), but not in the disease progression after a long follow-up period. Larger collaborative studies
are needed to confirm these results.
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Background
Five to ten percent of new acute myocardial infarction
(AMI) occur in individuals younger than 45 years [1]. An
Italian population registry (GISSI study) [2] reported a
similar, even if slightly lower, incidence (about 2%) in our
country at the end of the XXI century. At this age, AMI is
characterized by low mortality rates, less extensive coro-
nary artery disease (CAD), better residual left ventricular
function and a favourable prognosis in short and medium
follow-up [3].
As known, CAD is a multifactorial disease influenced by
environmental and genetic factors, in fact, in a younger
population smoking, dyslipidemia and familiarity are
more frequent than in older patients [2-4].
Although the role of these environmental factors in the
development of AMI has been clearly established, the role
of non-conventional risk factors remains undefined. In
the last few years a great interest has been focused on
genetic factors with the intent to find common markers
that could identify a subgroup of patients at higher risk of
death or with a worse prognosis in which new therapeutic
timings and interventions could be tested.
Particular interest has been focused on the renin-angi-
otensin-aldosterone system (RAAS) [5,6] in view of its
physiological role and of the established benefits of ACE
inhibitors therapy.
In the enzymatic cascade, angiotensinogen (AGT) is
cleaved by renin to produce angiotensin I, which is further
converted in the bioactive octapeptide angiotensin II
(ATII) through the action of angiotensin I converting
enzyme (ACE), a membrane-bound, zinc metallo-
endopeptidase involved in the metabolism of many small
peptides. The cellular effects of ATII in human adults are
mainly mediated by the angiotensin II type 1 receptor
(AGTR1). Aldosterone synthase (CYP11B2), sensible to
the effects of ATII, catalyses the final step of aldosterone
biosyntesis in adrenal glomerulosa. Because of the various
physiologic effects of ATII, including vasoconstriction,
promotion of vascular smooth muscle cells growth and
increase of extracellular collagen matrix synthesis, genetic
variation of the level of each RAAS component could
probably affect a wide variety of clinical phenotypes.
AGTR1 is known to play a pivotal role in the physiopatol-
ogy of several cardiovascular abnormalities [7-10], and
ACE and AGT are important in blood pressure homeosta-
sis [11,12], so it is not surprising that the genes coding for
members of the RAAS and its products are being investi-
gated in relation with AMI.
Aim of this study is to investigate the effects of ACE inser-
tion/deletion (ACE I/D), AGT1R A1166C and CYP11B2
C-344T polymorphisms on the occurrence and the long-




The study population was recruited from patients aged ≤
45 years, consecutively admitted between 1992 and 2002
to the Coronary Care Unit of the University Cardiology
Division of St. Giovanni Battista Hospital, Turin, who sat-
isfied the WHO criteria for diagnosis of acute myocardial
infarction [13].
Risk factors data were obtained from each patient includ-
ing smoking habits [14], hypercholesterolemia [15,16],
diabetes status [16], and hypertension [17].
A positive family history was considered if the patient had
a first-degree relative with CAD at the age < 55 years for
men or at < 65 years for women.
Patients with known congenital hypercoagulable status,
with declared cocaine abuse or with a known disease lim-
iting life expectance were excluded.
Each patient was matched with a healthy control subject,
recruited by General Practitioners, by sex, age (± 1 year)
and diabetes status. Control subjects were recruited in
general practitioners out patient' clinics. Exclusion criteria
for control cases were CAD and any known cardiomyopa-
thy, neoplasm, a severe illness limiting life expectance or
refusing consent.
The population recruited consisted of 201 patients and
201 matched controls.
Follow-up consisted in investigating new hospital admis-
sions, performing periodic ambulatory visits and tele-
phone interviews; follow-up was completed in 183
patients (91% of the starting population study) up to year
2005. The percentage of cases lost at follow-up is presum-
ably due to the long follow-up period (9 ± 4 years) related
to undetectable register variations.
Endpoint events considered were death, new AMI, and
revascularisation procedures (angioplasty or coronary
artery bypass graft surgery).
The study was performed according to the principles of
the Declaration of Helsinki, and informed consent was
obtained from each patient.BMC Medical Genetics 2007, 8:27 http://www.biomedcentral.com/1471-2350/8/27
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DNA genotyping
Genomic DNA was extracted from 200 μl of peripheral
blood lymphocytes according to a standard salting-out
method [18].
ACE: the 287 bp insertion/deletion (I/D) polymorphism
in intron 16 of the ACE gene was determined according to
the method of Zhu [19]. PCR products of 190 bp for the
D allele and 490 bp for the I allele were resolved on a 2%
agarose/0.5× TBE gel by ethidium bromide staining.
AGTR1: the A/C transversion at base 1166 in the 3'
untranslated region of the AT1R gene was determined as
described previously [20]. A 349 bp PCR product was
digested with DdeI for 2 hours at 37°C and resolved on a
2% agarose/0.5× TBE gel by ethidium bromide staining.
After restriction digest, the 1166C allele was cut into 139
and 210 bp fragments.
CYP11B2: The T/C transversion 344 base before the start
codon of the CYP11B2 gene was determined as previously
described [21]. The 273 bp PCR fragment represents the
wild-type T allele. After HaeIII digestion at 37°C, the frag-
ments were cut in a 202 bp (and little PCR fragments) if
the C allele occurred. Fragment length was resolved on a
2% agarose/0.5× TBE gel and then ethidium bromide
staining.
Statistical analysis
Allele and genotype frequencies of the analyzed polymor-
phisms were calculated by direct gene counting; a chi-
square test was used to test for the Hardy-Weinberg. Each
polymorphism and each risk factor, both in the acute and
follow-up phase, are expressed as percentages of the
respective strata and compared between patient strata by
means of the Pearson and Maximum-Likelihood Chi
square test (p value ≤ 0.05 considered significant).
In order to control for confounding variables, that may
have influenced occurrence and long-term prognosis of
AMI, multiple logistic regression analyses were performed
based on statistically relevant differences in gender and
conventional risk factors (smoking habits, family history,
hypercholesterolemia and hypertension) distributions
between both patients and controls and patients with and
without events. Among conventional risk factors, only
those more represented in CAD patients (p value ≤ 0.05)
were included in the multivariate analysis. The best subset
models were run applying odds ratio (OR) likelihood
scores.
The time course from the first AMI event to the considered
end-point (cardiac death, new myocardial infarction,
revascularization procedures) was analysed by the Kap-
lan-Meier method.
All the analysis performed using STATISTICA (StatSoft
Inc, Tulsa, Oklahoma, USA, version 7.1).
Results
The study population consisted in 201 patients and 201
controls (mean age 40 ± 4 years, range 25–45 years).
Male patients were 182 (90.5%), the most frequent risk
factors (Table 1) were cigarette smoking (72.9% in cases
vs 36.5% in controls, p < 0.001) and familial history of
CAD (58.6% vs 9.9%, p < 0.001). Significant differences
were observed also for hypercolesterolemia (52.7% vs
20.2%, p = 0.001) and for hypertension (31.5% vs 7.4%,
p = 0.002).
The allele and genotype frequencies are described in
details in Table 2.
Genotype frequencies in the overall sample fit the Hardy-
Weiberg equilibrium and were similar to those found in
other studies on Caucasian population.
We found a statistically significant association between
AMI and ACE polymorphism. The DD genotype alone,
reaching borderline significance in the univariate analysis
(42% in cases vs 31% in controls; p = 0.056) remained sig-
nificant also after adjustment for conventional risk factors
(p = 0.005) with a independent role on predicting events
(OR 2.39 CI 1.25–4.58, p = 0.008); whereas the CYP11B2
polymorphism (CC genotype, 27% vs 17%, p = 0.054)
reached borderline significance only in the crude analysis,
but lost an independent role after adjustment for con-
founders.
On the other hand, during the 9-year follow-up (65
events, including 13 deaths) we demonstrated a statisti-
cally significant difference between patients with or with-
out events concerning the AGTR1 (Table 3), in which the
heterozygous AC genotype resulted more represented in
the event group (p = 0.016).
The worst prognosis of patients with the AC genotype is
successively confirmed by the Kaplan-Meier event free
curves (Figure 1) considering the time course from the
Table 1: Conventional risk factors.
Smoke FamiCADa Hypertension Hypercolb
Control N (%) 74 (36.5) 20 (9.9) 15 (7.4) 41 (20.2)
Case N (%) 148 (72.9) 119 (58.6) 64 (31.5) 107 (52.7)
P value* <10-4 <10-4 0.002 0.001
* Pearson and M-L Chi-square; aFamiCAD: family history for CAD; 
bHypercol: hypercholesterolemia.BMC Medical Genetics 2007, 8:27 http://www.biomedcentral.com/1471-2350/8/27
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first AMI event to the different end-points (cardiac death,
myocardial infarction, revascularization procedures).
Furthermore in the multiple logistic regression analyses
the heterozygous AC genotype resulted as a protective pol-
ymorphisms on the onset of events at follow-up also
when correcting for conventional risk factors (OR 0.48 CI
0.24–0.96, p = 0.038). Instead prevalence of DD
homozygous genotype of ACE and CC genotype of
CYP11B2 did not diverge enough in the two groups to
reach statistical significance.
Discussion and conclusion
Epidemiological and clinical data from studies performed
on young adults with premature AMI have shown that the
occurrence of AMI in young Italian people is uncommon
(2% in the GISSI study) [1,2] and that the prognosis in
short-term outcome is good (mortality rate lower than
2%). For the risk factors profile, young patients have sig-
nificantly higher rates of smoking, dyslipidemia and fam-
ily history for CAD, compared with older patients [2]. A
promising but inherently difficult area of study is the
identification of genes that predispose to CAD.
The ECTIM study [11] first demonstrated that the
homozygote form of a deletion polymorphism of ACE
could be an independent risk factor for AMI.
In the current study, we compared the distributions of
conventional risk factors and RAAS polymorphisms (ACE,
AGTR1, CYP11B2) in a population of young patients with
AMI during the hospital recovery for acute event and after
a long-term follow-up.
ACE is expressed on the surface of the cell in many tissues
(particularly in lungs), but also circulates in a soluble
form obtained by the cleavage of the extracellular portion
from the endothelial cells [22]. The analyzed polymor-
phism is a 287 base pair Alu insertion/deletion (I/D) in
intron 16 of ACE gene in chromosome 17; DD genotype
Table 3: Genotype distribution according to follow-up events.
Events (%) No events (%) Chi square p value P value multiple 
regression*
OR for determinant 
polymorphisms
ACE I/D DD 25 (38%) 53 (45%) 0.252 0.191
ID 27 (42%) 52 (44%)
II 13 (20%) 13 (11%)
AGT1R AA 26 (40%) 68 (58%) 0.016 0.308 0.48 (0.24–0.96) p = 0.038
AC 35 (54%) 38 (32%)
CC 4 (6%) 12 (10%)
CYP11B2 CT 27 (42%) 52 (44%) 0.679 0.849
CC 21 (32%) 31 (26%)
TT 17 (26%) 35 (30%)
Total 65 (100%) 118 (100%)
* Corrected for gender, smoke, family history for CAD, hypertension, hypercholesterolemia.
Table 2: Genotype distribution in patients and in healthy controls.
Case (%) Control (%) Chi square p 
value
P value multiple 
regression*
OR for determinant 
polymorphisms
ACE I/D DD 84 (42%) 63 (31%) 0.056 0.005 2.39 (1.25–4.58) p = 0.008
ID 88 (44%) 96 (48%)
II 29 (14%) 42 (21%)
AGT1R AA 100 (50%) 117 (58%) 0.231 0.214
AC 84 (42%) 69 (34%)
CC 17 (8%) 15 (7%)
CYP11B2 CT 87 (43%) 97 (48%) 0.054 0.978
CC 55 (27%) 35 (17%)
TT 59 (29%) 69 (34%)
Total 201 (100%) 201 (100%)
* Corrected for gender, smoke, family history for CAD, hypertension and hypercholesterolemia.BMC Medical Genetics 2007, 8:27 http://www.biomedcentral.com/1471-2350/8/27
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is associated with increased serum and cellular concentra-
tions of ACE, that results in enhanced convertion of angi-
otensin I in angiotensin II [19].
Cambien [5] first demonstrated a possible role of DD gen-
otype as cardiovascular risk factor; most of the subsequent
studies have shown no significant effects of this polymor-
phism on the extent of CAD but mainly on the onset of
acute coronary syndrome, data suggesting a possible role
in the mechanism involving plaque instability, ulceration
and thrombosis [22].
In a recent study Palmer et al. [23] conclude that ACE I/D
genotype may provide additional prognosis information
in patients with AMI, suggesting an association with DD
genotype and mortality after cardiac events that was
excluded in previous studies [24,25].
In our work we support the role of DD as a relevant risk
factor in the acute phase, with an independent role also
when adjusting for conventional risk factors. This result is
of high interest if thought as a new identifiable and mod-
ifiable (ACE inhibitors, since the DD genotype enhances
cellular concentration of ACE) risk factor in specific sub-
groups (family history for CAD) of patients. Conversely,
accordingly to previous literature data [24,25], we did not
find any association between DD and mortality or other
events (new AMI, revascularization procedures, angi-
oplasty or coronary bypass graft surgery) after AMI.
AGTR1 is expressed mainly in vascular smooth muscle
cells and in the myocardium. A polymorphism in the 3'
untranslated region of AGTR1 gene was identified [11],
corresponding to an A→C transversion at nucleotide posi-
tion 1166 of the mRNA sequence.
An association between AGTR1-C allele and a modified
response of the receptor to angiotensin II [5] has been sug-
gested, thus justifying the reported statistically significant
correlation of AGT1R-CC with increased cardiovascular
risk, together with ACE DD polymorphism [5,6], in a syn-
ergistic effect.
However, Andrikopoulos et al. [10] found that there was
no significant association among patients with the
A1166C polymorphism in the AGTR1 gene and increased
mortality for AMI.
Our study, instead, after a long-term follow-up shows an
unfavourable role of AC genotype after the acute coronary
event; however, this result needs to be confirmed in larger
studies.
The human aldosterone synthase (CYP11B2) gene is
located on chromosome 8 and the polymorphism was
studied in the promoter region of the gene at nucleotide
344 from the translation start site, where the residue could
be cytosine or thymidine.
The activity of the CYP11B2 gene is primarily regulated by
the renin-angiotensin system through the actions of angi-
otensin II.
This polymorphism has been correlated to increased cir-
culating levels of aldosterone, thus influencing arterial
hypertension, cardiac fibrosis and, consequently, both
diastolic dysfunction and ventricular remodelling evolu-
tion after AMI [26].
Kupari et al observed, in young Finnish subjects, that the
CC genotype of CYP11B2 polymorphism is a strong pre-
dictor of left ventricular diameters, mass and ventricular
filling fraction.
It has been showed that smoking and dislypidemia are
more potent risk factors for nonfatal MI in males who
have the C allele of CYP11B2 [27].
In the present study, we found a statistically significant
association between CYP11B2 polymorphisms and AMI,
suggesting a possible role as cardiac risk factor, but not
independently from the conventional ones.
In conclusion our work, although if based on a limited
sample size, has the potential of a long follow-up period
after the first cardiac event. Our results show that poly-
morphisms in RAAS genes could be important in the
Kaplan Meier curves for AGT1R polymorphisms Figure 1
Kaplan Meier curves for AGT1R polymorphisms.BMC Medical Genetics 2007, 8:27 http://www.biomedcentral.com/1471-2350/8/27
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onset of a first AMI event in young patients (ACE,
CYP11B2 polymorphisms) as in the disease progression.
Many contradictory results have been published on RAAS
polymorphisms in the attempt to find out new associa-
tions with clinical-therapeutic features or biochemical
determinations.
In a multifactorial disease like CAD, in which the weight
of conventional risk factors is so high especially in young
people, and in which genetic profile is so heterogeneous
due to many low penetrant candidate genes possibly
involved, the clinical usefulness of genetic findings needs
to be carefully discussed.
The role of different polymorphisms in individual risk
assessment for primary and secondary prevention pro-
grams is strictly linked to the possible interaction with
many known conventional risk factors.
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